Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
- Conditions
- Advanced CancerMetastatic CancerColorectal CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9
- Registration Number
- NCT02860780
- Locations
- 🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇩🇪For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
- Conditions
- Metastatic MelanomaMetastatic Non-small Cell Lung CancerAdvanced CancerColorectal Cancer
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 210
- Registration Number
- NCT02857270
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: LY3039478
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 11
- Registration Number
- NCT02836600
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Chiba, Japan
A Study of Galcanezumab in Healthy Participants.
- Conditions
- Healthy
- Interventions
- Biological: Galcanezumab
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 160
- Registration Number
- NCT02836613
- Locations
- 🇺🇸
Covance Clinical Research Inc, Evansville, Indiana, United States
🇺🇸Covance, Dallas, Texas, United States
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
- Conditions
- Stage IV Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02831491
A Study of LY3023414 Formulations and the Effect of Food
- Conditions
- Healthy
- Interventions
- Drug: LY3023414 Test FastedDrug: LY3023414 Test FedDrug: LY3023414 Reference Fasted
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02818335
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT02806960
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada
A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT02806973
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
- Conditions
- Episodic Cluster HeadacheChronic Cluster Headache
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 165
- Registration Number
- NCT02797951
- Locations
- 🇺🇸
California Medical Clinic for Headache, Santa Monica, California, United States
🇺🇸Atlanta Center of Medical Research, Atlanta, Georgia, United States
🇨🇦Stroyan Research, Toronto, Ontario, Canada
Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02792725
- Locations
- 🇺🇸
UCLA Medical Center, Santa Monica, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States